# A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)

> **NCT06643143** · PHASE2 · WITHDRAWN · sponsor: **Inhibikase Therapeutics**

## Conditions studied

- Pulmonary Arterial Hypertension (PAH)
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

## Interventions

- **DRUG:** IkT-001Pro
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06643143
- **Lead sponsor:** Inhibikase Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-30
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study has undergone sponsorship and design changes.
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643143, "A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06643143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*